Moderna shares have gained nearly 575% this year, on track for a record annual performance. The move follows positive Phase 3 data for its personalized mRNA cancer vaccine in melanoma, co-developed with Merck.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
